Drug intelligence / Profile preview

NP-500

Development stage: Preclinical
Lead developer: Napo Pharmaceuticals
Administration: Oral, Rectal, Intramuscular, Intravenous

Overview

NP-500 is a drug exclusively licensed by Jaguar Animal Health from Napo Pharmaceuticals for all veterinary treatment uses and indications in all animal species, excluding humans. It is being developed for conditions such as obesity-related metabolic dysfunction in dogs and cats, diabetes mellitus, and equine laminitis. Patents covering NP-500 were originally submitted by Napo in April 2011, and the U.S. Patent and Trademark Office issued Notices of Allowance for two pending patent applications.

Beyond the preview

Go deeper on NP-500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-500.

Explore the full profile